Literature DB >> 9049224

B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C.

K Mochizuki1, N Hayashi, K Katayama, N Hiramatsu, T Kanto, E Mita, T Tatsumi, N Kuzushita, A Kasahara, H Fusamoto, T Yokochi, T Kamada.   

Abstract

Cytotoxic T lymphocytes (CTL) are closely related to the mechanism of liver injury in chronic viral hepatitis. Recently, it has been suggested that antigen-specific T cell activation requires both presentation of antigen by major histocompatibility complex (MHC) molecules and the delivery of costimulatory signals. Such signals are provided by B7/BB-1, one of the most important accessory molecules, sufficient for causing antigen-specific MHC-restricted T cell activation. To evaluate the role of B7/BB-1 in chronic hepatitis C, we immunohistochemically studied its expression in liver tissues obtained from 61 patients with hepatitis C virus (HCV) infection and compared them based on hepatitis activity. In HCV-infected liver, B7/BB-1 was strongly expressed in the cytoplasm of hepatocytes. B7/BB-1-positive cells accompanied liver-infiltrating lymphocytes and were mainly detected in the periportal region. B7/BB-1 expression was closely correlated with the activity of viral hepatitis as evaluated from scores of periportal or intralobular inflammation and necrosis, or serum alanine transferase (ALT) levels. Further study by immunostaining with anti-HCV core and anti-human leukocyte antigen (HLA) class I antibody showed B7/BB-1 positive cells near HCV core antigen- and HLA class I-positive cells, with B7/BB-1-positive cells mostly included among HLA class I-positive cells. These findings suggested that B7/BB-1 expression by hepatocytes may be induced by HCV infection and may trigger generation and activation of CTL, which may cause damage to HCV-infected HLA class I-expressing hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049224     DOI: 10.1002/hep.510250337

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Regulation of host cell transcriptional physiology by the avian pneumovirus provides key insights into host-pathogen interactions.

Authors:  Shirin Munir; Vivek Kapur
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice.

Authors:  Jiabin Yan; Zuliang Jie; Lifei Hou; Joao L Wanderley; Lynn Soong; Shalini Gupta; Suimin Qiu; Tehsheng Chan; Jiaren Sun
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

4.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Authors:  A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

5.  Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization.

Authors:  R Patzwahl; V Meier; G Ramadori; S Mihm
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury.

Authors:  Jiaren Sun; Batbayar Tumurbaatar; Junhui Jia; Hong Diao; Francis Bodola; Stanley M Lemon; Wendell Tang; David G Bowen; Geoffrey W McCaughan; Patrick Bertolino; Teh-Sheng Chan
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  CD28-negative CD8-positive cytotoxic T lymphocytes mediate hepatocellular damage in hepatitis C virus infection.

Authors:  Kazutaka Kurokohchi; Tsutomu Masaki; Keiji Arima; Yoshiaki Miyauchi; Toshiharu Funaki; Hirohito Yoneyama; Shuhei Yoshida; Akihiro Deguchi; Seiji Nakai; Seishiro Watanabe; Shigeki Kuriyama
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

8.  Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV.

Authors:  Chan Ran You; Su-Hyung Park; Sung Won Jeong; Hyun Young Woo; Si Hyun Bae; Jong Young Choi; Young Chul Sung; Seung Kew Yoon
Journal:  Gut Liver       Date:  2011-11-21       Impact factor: 4.519

9.  Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.

Authors:  Claudia Mascia; Serena Vita; Paola Zuccalà; Raffaella Marocco; Tiziana Tieghi; Stefano Savinelli; Raffaella Rossi; Marco Iannetta; Irene Pozzetto; Caterina Furlan; Fabio Mengoni; Claudio Maria Mastroianni; Vincenzo Vullo; Miriam Lichtner
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

10.  A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression.

Authors:  Elias A Said; Iman Al-Reesi; Marwa Al-Riyami; Khalid Al-Naamani; Shadia Al-Sinawi; Mohammed S Al-Balushi; Crystal Y Koh; Juma Z Al-Busaidi; Mohamed A Idris; Ali A Al-Jabri
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.